Following the first White Paper on Prostate Cancer on lower risk and mortality rate of Prostate Cancer, the European Association of Urology (EAU) has initiated a second Policy Paper addressing the need to reconsider structured population-based PSA screening for prostate cancer.
In close conjunction with medical experts, representatives from related medical societies and patient advocacy group this Policy Paper was prepared, covering key topics such as the latest evidence, consequences of not performing PSA screening, overdiagnosis & overtreatment, and six recommendations as a call to action:
- The 2003 Council Recommendations on population-based screening need to be urgently reviewed, with prostate cancer added to the list of cancers to be addressed.
- Member States should already support a policy update on prostate cancer screening through their work on the EU Joint Action, the Innovative Partnership for Action Against Cancer (IPAAC)
- MEPs should ensure that European action on Prostate Cancer screening is included in the group manifestos as they prepare for Europe elections
- The new college of Commissioners mandated in 2019 should be empowered by the European Parliament and Member States to support Member States with European guidelines on prostate cancer screening.
- Member States should bring good practice on prostate cancer screening to the Steering Group on Health Promotion, Disease Prevention and Management of non-communicable diseases.
- European Commission encouraged to channel more support and funding to Prostate Cancer screening and research
Download the full EAU Policy Paper on PSA Screening